| Neptune Technologies & Bioressources Inc. Reports Second Quarter Results - Record EBITDA |
| Friday, January 26 2007 | |||
Neptune Technologies & Bioressources Inc. Reports Second Quarter Results - Record EBITDALaval, Quebec, Canada, January 26th, 2007 - Neptune Technologies & Bioressources Inc., (TSX Venture Exchange: NTB), «Neptune» today announced its results for the Second quarter ended November 30th, 2006. Neptune recorded its highest EBITDA quarter to date. Neptune’s Highlights:
“The reorganisation of our Sales and Marketing department is starting to pay off. Neptune has realized its best EBITDA quarter and second best sales quarter to date. We are very pleased with Neptune’s overall performance even though the existing stock option plan in conjunction with the significant share price increase over the six months period ending November 30, 2006 affected the bottom line without fortunately any impact on the cash flow,” stated André Godin, Vice-President, Administration and Finance for Neptune Technologies & Bioressources Inc. About Neptune Technologies & Bioressources Inc. : https://www.neptunebiotech.com Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets. Neptune Technologies and Acasti Pharma Contact:
Neptune Technologies & Bioressources Inc. Acasti Pharma Inc. Toni Rinow, Ph.D., MBA Corporate Development & Investor Relations (450) 687-2262 This e-mail address is being protected from spambots, you need JavaScript enabled to view it
|